For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Congress shouldn’t rely on incomplete FTC PBM study
Lawmakers are making a last-minute push to regulate the practices of pharmacy benefit managers (PBMs) during the lame duck session. However, it would be a…
Wall Street Journal
A Thumb on the Scale for Wegovy
The Biden administration announced one more bit of executive overreach on its way out the door. On Nov. 26, the Centers for Medicare and Medicaid…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
Search Posts
National Review
When Science Is Not Science
Just 22 percent of all adults and 41 percent of those 65 and older — the most vulnerable group — have received the updated 2023–24 Covid-19 vaccine.
Blog
When the FTC’s anti-merger goals overshadow the prospect of saving lives
The Fifth Circuit Court of Appeals recently issued a ruling on the important case of Illumina-Grail v. Federal Trade Commission. A unanimous 3-0…
Beritbart
Unholy Alliance Between the Left and Big Pharma Threatens More Big Government Intervention in Health Care
CEI’s Joel Zinberg is cited in Breitbart on the big government intervention in healthcare: Economic experts recognize that the very foundation of a free…
City Journal
A “Coordinated Campaign”
The Covid-19 pandemic revealed a split between those who believe that the government has broad authority to control every aspect of the economy and society…
Washington Times
Cutting-edge drugs could vanish under Biden’s unprecedented move to seize patents
CEI’s Dr. Joel Zinberg is cited in the Washington Times on the Biden Administration’s move to seize patents: Dr. Joel Zinberg, a senior fellow…
National Review
Another FDA Power Grab
The comment period for the Food and Drug Administration’s latest power grab has just concluded. Roughly 20,000 comments were submitted addressing the FDA’s proposed rule which…
